The Efficacy and Safety of PAD and VAD Regimens in Treatment of Patients with Multiple Myeloma
- VernacularTitle:PAD和VAD方案治疗MM患者临床有效性及安全性比较
- Author:
Yunyan WAN
;
Yanfen HE
;
Jianping WANG
- Publication Type:Journal Article
- Keywords:
Bortezomib;
Vincristine;
Adriamycin;
Dexamethasone;
Multiple myeloma
- From:
Journal of Kunming Medical University
2014;(1):109-111,124
- CountryChina
- Language:Chinese
-
Abstract:
Objective The purpose of this study was to investigate the efficacy and safety of bortezomib +doxorubicin + dexamethasone (PAD) regimen in the treatment of patients with multiple myeloma (MM) . Methods Thirty-eight patients with MM in our hospital were selected and randomly divided into observation group and control group with 19 cases in each. The observation group was treated with PAD regimen and the control group was treated with VAD regimen (vincristine+doxorubicin+dexamethasone) . Clinical efficacy and adverse reaction were compared between the two groups. Results The effective rate and total effective rate of the observation group were 52.63%and 78.95%respectively, which were significantly higher than those of the control group ( <0.05 and <0.05) . There was no statistical difference in the incidence of adverse events between the two groups ( >0.05) . Conclusion PAD regimen could improve the clinical effect of treating patients with MM, and the adverse reactions can be tolerated. It is safe and worthy of clinical application.
